Review of the British Thoracic Society Winter Meeting 2011, 7-9 December, London, UK

Thorax

Volumn 67, Issue 3, 2012, Pages 258-262

  Bayes, Hannah Kelly ^a   Church, Alistair Colin ^b   Fisher, Andrew J ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Scottish Pulmonary Vascular Unit ^*  (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CARBOPLATIN; CISPLATIN; DABIGATRAN; GEMCITABINE; HEPARIN; IVACAFTOR; PROTON PUMP INHIBITOR; RIVAROXABAN;

BLOOD CLOT LYSIS; BRITISH ASSOCIATION FOR LUNG RESEARCH; BRITISH LUNG FOUNDATION; CANCER SURGERY; CYSTIC FIBROSIS; EMBOLECTOMY; GENE MUTATION; HEALTH CARE ORGANIZATION; HUMAN; INNATE IMMUNITY; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; PRIORITY JOURNAL; PULMONARY VASCULAR DISEASE; REVIEW; SYMPOSIUM; UNITED KINGDOM;

EID: 84857413539     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-201597     Document Type: Review

References (60)

1. Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010;6:25-33.
2. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005;60:55-9. (Pubitemid 40101019)
3. Norez C, Antigny F, Noel S, et al. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am J Respir Cell Mol Biol 2009;41:217-25.
4. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18.
5. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011;108:18843-8.
6. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72.
7. Ahrens R, Rodriguez S, Yen K, et al. VX-770 in Subjects 6 to 11 Years with Cystic Fibrosis and the G551D-CFTR Mutation. NACF Conference, 2011:A203.
8. Cox MJ, Allgaier M, Taylor B, et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PloS One 2010;5:e11044.
9. Tunney MM, Klem ER, Fodor AA, et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011;66:579-84.
10. Cox MJ, Jones A, Loebinger M, et al. Mucoidy and the microbiome: community composition in relation to the presence of culturable, mucoid Pseudomonas Aeruginosa. Thorax 2011;66(Suppl IV):A24.
11. Flight W, Mutton K, Isalska B, et al. A comparison of three different specimen types for the diagnosis of viral respiratory infections in adults with cystic fibrosis. Thorax 2011;66(Suppl IV):A23.
12. Flight W, Mutton K, Webb A, et al. Clinical efficacy of seasonal influenza vaccination in adults with cystic fibrosis. Thorax 2011;66(Suppl IV):A23.
13. Hurley MN, Forrester DL, Smyth AR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst Rev 2010;(10): CD008037.
14. Regamey N, Jeffery PK, Alton EW, et al. Airway remodelling and its relationship to inflammation in cystic fibrosis. Thorax 2011;66:624-9.
15. McNally P, Ervine E, Shields MD, et al. High concentrations of pepsin in bronchoalveolar lavage fluid from children with cystic fibrosis are associated with high interleukin-8 concentrations. Thorax 2011;66:140-3.
16. Geraghty P, Rogan MP, Greene CM, et al. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloproteinase 2 in vivo and in vitro. Thorax 2008;63:621-6. (Pubitemid 351969256)
17. Bayes H, Evans T. Pseudomonas aeruginosa induces apoptosis in human dendritic cells: a potential mechanism to evade pulmonary immune responses. Thorax 2011;66(Suppl IV):A24.
18. Jimenez D, Aujesky D, Moores L, et al. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax 2011;66:75-81.
19. Torbicki A. Acute and long term management of pulmonary embolism. Heart 2010;96:1418-24.
20. Barritt DW. The diagnosis and management of pulmonary embolism. Postgrad Med J 1964;40:414-22.
21. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level metaanalysis. J Thromb Haemost 2010;8:2436-42.
22. Seimetz M, Parajuli N, Pichl A, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011;147:293-305.
23. Corte TJ, Wort SJ, Gatzoulis MA, et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009;64:883-8.
24. Corte TJ, Gatzoulis MA, Parfitt L, et al. The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology 2010;15:1226-32.
25. Haddad F, Kudelko K, Mercier O, et al. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovascular Dis 2011;54:154-67.
26. Toshner M, Ormiston M, Dunmore B, et al. Characterisation of the endothelial outgrowth cell. Thorax 2011;66(Suppl IV):A33.
27. Church A, Wadsworth R, Bryson G, et al. Inhibition of p38 mitogen-activated protein kinase (MAPK) prevents the development of experimental pulmonary hypertension. Thorax 2011;66(Suppl IV):A33.
28. Swift A, Rajaram S, Condliffe R, et al. Diagnostic utility and prognostic value of quantitative cardiac MR indices in patients with suspected pulmonary hypertension. Thorax 2011;66(Suppl IV):A34.
29. Ling Y, on behalf of the Pulmonary Hypertension Physicians Association of the UK and Ireland. Ireland oboPHPAoUa. Influence of age on clinical phenotypes of incident idiopathic pulmonary arterial hypertension. Results from the pulmonary hypertension registry of the UK and Ireland. Thorax 2011;66(Suppl IV):A34.
30. Long L, Yang X, Morrell N, et al. BMPR-2 R899X knock-in mice developed age-related pulmonary hypertension. Thorax 2011;66(Suppl IV):A46.
31. Soon E, Crosby A, Southwood M, et al. Heterozygous loss of BMPR-II predisposes to inflammatory cytokine secretion and pulmonary vascular smooth muscle proliferation. Thorax 2011;66(Suppl IV):A47.
32. Cannon J, Bradshaw C, Smith J, et al. The bone morphogenetic protein type II receptor is critical for venous angiogenesis in zebrafish. Thorax 2011;66(Suppl IV): A47.
33. Dunmore B, Long L, Yang X, et al. The anti-malarial drug and lysosomal inhibitor, chloroquine increases cell surface expression BMPR-II. Thorax 2011;66(Suppl IV): A46.
34. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011;377:127-38.
35. NAEDI. http://info.cancerresearchuk.org/spotcancerearly/naedi/AboutNAEDI/ (accessed 18 Jan 2012).
36. Athey VL, Suckling RJ, Tod AM, et al. Early diagnosis of lung cancer: evaluation of a community-based social marketing intervention. Thorax. Published Online First: 2 November 2011. doi:10.1136/thoraxjnl-2011-200714
37. Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax 2011;66:315-19.
38. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
39. Holmberg L, Sandin F, Bray F, et al. National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up. Thorax 2010;65:436-41.
40. Agostini P, Cieslik H, Rathinam S, et al. Postoperative pulmonary complications following thoracic surgery: are there any modifiable risk factors? Thorax 2010;65:815-18.
41. Rintoul R, Annema J, Tournoy K, et al. Cost-effectiveness and quality of life results from the ASTER study: endobronchial and endoscopic ultrasound versus surgical staging in potentially resectable lung cancer. Thorax 2011;66(Suppl IV):A27.
42. Navani N, Lawrence D, Kolvekar S, et al. EBUS-TBNA prevents mediatinoscopies in patients with isolated mediatinal lymphadenopathy: a prospective clinical trial and cost minimisation analysis. Thorax 2011;66(Suppl IV):A27.
43. Lee R, McClean E, Quinn A, et al. Gene expression profiling of endobronchial ultrasound derived cytological aspirates from hilar and mediastinal lymph nodes in NSCLC. Thorax 2011;66(Suppl IV):A28.
44. 2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC. Thorax 2011;66(Suppl IV):A41.
45. Billingham L, Gaunt P, Jarrett HW, et al. Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Group phase III trial in 1363 patients. Thorax 2011;66(Suppl IV):A41.
46. 2 and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC):correlations with clinical outcomes. Thorax 2011;66(Suppl IV):A41.
47. Jarrett H, Hill M, Billingham L, et al. S88 Day case cisplatin delivery for advanced NSCLC patients: faster, cheaper, more desirable. Thorax 2011;66 (Suppl IV):A42.
48. Steer H, Cleaver A, Nowak A, et al. Chemo-immunotherapy of mesothelioma: depletion of established, suppressive CD4 T cells is critical to achieving cures in a murine model. Thorax 2011;66(Suppl IV):A29.
49. Sage E, Kolluri K, Giangreco A, et al. Mesenchymal stem cells expressing TRAIL induce apoptosis in malignant pleural mesothelioma. Thorax 2011;66(Suppl IV):A29.
50. Singh S, Singh U, Elkington P, et al. Matrix metalloproteinase-driven tissue destruction in human tuberculosis(TB) is mediated by Th-17 cytokines and the PI3K/P110A/P70S6K cascade. Thorax 2011;66(Suppl 4):A1.
51. Chalmers J, Kilpatrick D, McHugh B, et al. Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis. Thorax 2011;66(Suppl 4):A1.
52. Roach K, Coward W, Feghali-Bostwick C, et al. The KCa3.1 K+ channel mediates wound healing in human myofibroblasts. Thorax 2011;66(Suppl 4):A2.
53. Farahi N, Condliffe A, Singh N, et al. Measuring eosinophil kinetics in humans. Thorax 2011;66(Suppl 4):A2.
54. Davies G, Davies J, Gill D, et al. Safety and expression of a single dose of lipid-mediated CFTR gene therapy to the upper and lower airways of patients with cystic fibrosis. Thorax 2011;2011(Suppl 4):A2.
55. Hameed A, Arnold N, Pickworth J, et al. TRAIL is a potential novel therapeutic target in pulmonary arterial hypertension. Thorax 2011;66(Suppl 4):A3.
56. Harridge SD, Kryger A, Stensgaard A. Knee extensor strength, activation, and size in very elderly people following strength training. Muscle Nerve 1999;22:831-9. (Pubitemid 29330029)
57. Bougault V, Turmel J, Boulet LP. Airway hyperresponsiveness in elite swimmers: is it a transient phenomenon? J Allergy Clin Immunol 2011;127:892-8.
58. Pedersen L, Elers J, Backer V. Asthma in elite athletes: pathogenesis, diagnosis, differential diagnoses, and treatment. Phys Sportsmed 2011;39:163-71.
59. Turcotte H, Langdeau JB, Thibault G, et al. Prevalence of respiratory symptoms in an athlete population. Respir Med 2003;97:955-63. (Pubitemid 36944127)
60. Grainge CL, Lau LC, Ward JA, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011;364:2006-15.